Results of a reevaluation of cardiovascular outcomes in the RECORD trial

Conclusions: Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results.

Source: American Heart Journal - June 6, 2013 Category: Cardiology Authors: Kenneth W. Mahaffey, Gail Hafley, Sheila Dickerson, Shana Burns, Sandra Tourt-Uhlig, Jennifer White, L. Kristin Newby, Michel Komajda, John McMurray, Robert Bigelow, Philip D. Home, Renato D. Lopes Tags: Diabetes and Metabolism Source Type: research